Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 9/20 | 0.52 |
| ▸ | NPC1 | O15118 | 8/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9157246 | 0.87 | MAPT (0.62) | MAPTALDH1A1LMNARAB9ANPC1 | |
| SCHEMBL6677275 | 0.84 | MAPT (0.73) | MAPTALDH1A1LMNARAB9ANPC1 | |
| SCHEMBL2986961 | 0.84 | MAPT (0.48) | MAPTALDH1A1LMNARAB9ANPC1 | |
| SCHEMBL1981549 | 0.83 | MAPT (0.51) | MAPTALDH1A1LMNARAB9ANPC1 | |
| SCHEMBL30199709 | 0.82 | ALDH1A1 (0.53) | MAPTALDH1A1RAB9ANPC1KMT2A | |
| SCHEMBL228082 | 0.82 | ALDH1A1 (0.53) | MAPTALDH1A1RAB9ANPC1KMT2A | |
| SCHEMBL5004832 | 0.81 | ALDH1A1 (0.69) | MAPTALDH1A1LMNARAB9ANPC1 | |
| SCHEMBL22291692 | 0.81 | MAPT (0.69) | MAPTALDH1A1LMNARAB9ANPC1 | |
| SCHEMBL9200645 | 0.80 | ALDH1A1 (0.50) | MAPTALDH1A1LMNARAB9ANPC1 | |
| SCHEMBL2987569 | 0.80 | TLR4 (0.53) | MAPTLMNARAB9ANPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351570-B2 | Disubstituted alkyne derivatives | MERCK PATENT GMBH (DE) | 2025-07-08 | — | — | US | disclosed |
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | VIVIDION THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| US-20230052586-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-02-16 | — | — | US | disclosed |
| EP-3898588-B1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-01-11 | — | — | EP | disclosed |
| WO-2021249969-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF CANCER DISEASES | MERCK PATENT GMBH (DE) | 2021-12-16 | — | — | WO | disclosed |
| EP-3898588-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | Merck Patent GmbH (DE) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020127960-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-06-25 | — | — | WO | disclosed |
| US-20080132551-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | PFIZER INC | 2008-06-05 | — | — | US | disclosed |
| EP-1611128-A2 | POSITIVE ALLOSTERIC MODULATORS OF THE NICOTINIC ACETYLCHOLINE RECEPTOR | Pharmacia & Upjohn Company LLC (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004085433-A2 | POSITIVE ALLOSTERIC MODULATORS OF THE NICOTINIC ACETYLCHOLINE RECEPTOR | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | KRAS, HRAS, NRAS | MAPT 4348/4885ALDH1A1 4625/4885LMNA 3764/4885 |
| US-12351570-B2 | Disubstituted alkyne derivatives | BRCA1, MYC, PCNA | MAPT 3982/4885ALDH1A1 414/4885LMNA 1582/4885 |
| US-20230052586-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | BRCA1, MYC, PCNA | MAPT 3982/4885ALDH1A1 414/4885LMNA 1582/4885 |
| US-20080132551-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | CHRNA1, CHRNA7, CHRNA5 | MAPT 1408/4885ALDH1A1 2361/4885LMNA 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.